Prognostic utility of preoperative platelet-to-albumin ratio in surgically treated oral cavity cancer patients

Head Neck. 2024 Feb;46(2):386-397. doi: 10.1002/hed.27592. Epub 2023 Dec 10.

Abstract

Background: This study aimed to explore the prognostic utility of the preoperative platelet-to-albumin ratio (PAR) among patients with oral cavity squamous cell carcinoma (OSCC).

Methods: We retrospectively reviewed of 355 patients with surgically-treated OSCC between 2008 and 2017. The optimal PAR cutoff for patient stratification was determined through X-tile analysis. Prognostic variables for disease-free survival (DFS) and overall survival (OS) were identified using Cox proportional hazards models. We developed a PAR-based nomogram to predict personalized OS.

Results: We determined the optimal PAR cutoff to be 7.45. A PAR of ≥7.45 was an independent negative prognostic factor for DFS and OS (hazard ratio = 1.748 and 2.386; p = 0.005 and p < 0.001, respectively). The developed nomogram demonstrates the practical utility of PAR and accurately predicts personalized OS.

Conclusions: The preoperative PAR is a promising and cost-effective prognostic biomarker for patients with surgically-treated OSCC; the PAR-based nanogram accurately predicts OS for such patients.

Keywords: disease-free survival; nomogram; oral cavity cancer; overall survival; platelet-to-albumin ratio.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins*
  • Carcinoma, Squamous Cell* / pathology
  • Humans
  • Mouth / pathology
  • Prognosis
  • Retrospective Studies

Substances

  • Albumins